MX2019011252A - Anticuerpos anti-c5a y usos de los mismos. - Google Patents

Anticuerpos anti-c5a y usos de los mismos.

Info

Publication number
MX2019011252A
MX2019011252A MX2019011252A MX2019011252A MX2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A
Authority
MX
Mexico
Prior art keywords
complement
antibody
individual
antibodies
relates
Prior art date
Application number
MX2019011252A
Other languages
English (en)
Inventor
Song Wenchao
Sato Sayaka
Miwa Takashi
Gullipalli Damodar
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2019011252A publication Critical patent/MX2019011252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a la inhibición de la señalización del complemento usando un anticuerpo anti-C5a; específicamente, la invención se refiere a métodos para tratar una enfermedad mediada por el complemento o trastorno mediado por el complemento en un individuo, poniendo en contacto al individuo con un anticuerpo anti-C5a.
MX2019011252A 2017-03-23 2018-03-23 Anticuerpos anti-c5a y usos de los mismos. MX2019011252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475573P 2017-03-23 2017-03-23
PCT/US2018/023927 WO2018175833A1 (en) 2017-03-23 2018-03-23 Anti-c5a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011252A true MX2019011252A (es) 2020-01-23

Family

ID=63585782

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011252A MX2019011252A (es) 2017-03-23 2018-03-23 Anticuerpos anti-c5a y usos de los mismos.

Country Status (13)

Country Link
US (2) US11274146B2 (es)
EP (1) EP3600421A4 (es)
JP (2) JP7251792B2 (es)
KR (1) KR20190132665A (es)
CN (1) CN110709101B (es)
AU (1) AU2018237300A1 (es)
BR (1) BR112019019595A2 (es)
CA (1) CA3057146A1 (es)
EA (1) EA201992248A1 (es)
IL (1) IL269428A (es)
MX (1) MX2019011252A (es)
SG (1) SG11201908744PA (es)
WO (1) WO2018175833A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997745A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
MA45235A (fr) 2016-06-14 2019-04-17 Regeneron Pharma Anticorps anti-c5 et leurs utilisations
IL269122B2 (en) * 2017-03-06 2024-07-01 Univ Pennsylvania Antibodies against C5 and their uses
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20220332802A1 (en) * 2019-06-06 2022-10-20 Children's Hospital Medical Center Methods and compositions for treatment of neurodegeneration
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
EP3372243A1 (en) * 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2009103113A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd HUMANIZED ANTI-C5aR ANTIBODIES
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
EA025245B1 (ru) * 2009-05-08 2016-12-30 Вэксинекс, Инк. Антитела против cd100 и способы их применения
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
SI2563813T1 (sl) * 2010-04-30 2015-12-31 Alexion Pharmaceuticals, Inc. Protitelesa anti-C5A in postopki uporabe protiteles
CN106977603B (zh) 2010-05-04 2020-11-27 戊瑞治疗有限公司 结合csf1r的抗体
PE20140190A1 (es) 2010-08-27 2014-02-10 Stem Centrx Inc Moduladores de proteinas notum y metodos de uso
WO2012088247A2 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
SG10202108240VA (en) * 2011-04-28 2021-09-29 Sbi Biotech Co Ltd ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
DK3166973T3 (da) * 2014-07-10 2020-04-06 Univ Zuerich Immunstimulerende monoklonale antistoffer mod human interleukin-2
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
IL269122B2 (en) * 2017-03-06 2024-07-01 Univ Pennsylvania Antibodies against C5 and their uses
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體

Also Published As

Publication number Publication date
JP7251792B2 (ja) 2023-04-04
JP2020511505A (ja) 2020-04-16
BR112019019595A2 (pt) 2020-04-14
CA3057146A1 (en) 2018-09-27
AU2018237300A1 (en) 2019-10-17
EP3600421A4 (en) 2021-01-06
US20200148754A1 (en) 2020-05-14
US11274146B2 (en) 2022-03-15
RU2019133479A (ru) 2021-04-23
KR20190132665A (ko) 2019-11-28
IL269428A (en) 2019-11-28
WO2018175833A1 (en) 2018-09-27
EP3600421A1 (en) 2020-02-05
CN110709101A (zh) 2020-01-17
RU2019133479A3 (es) 2021-11-24
US20220153824A1 (en) 2022-05-19
EA201992248A1 (ru) 2020-02-06
CN110709101B (zh) 2024-05-07
JP2022183224A (ja) 2022-12-08
SG11201908744PA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
ZA201905866B (en) Anti-c5 antibodies and uses thereof
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
PH12019502283A1 (en) Anti-lag3 antibodies
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2019014291A (es) Metodo de tratamiento.
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA202190698A1 (ru) Гуманизированные анти-c5 антитела и их применение